Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korea...
S.Korea’s CDMO giant Samsung Biologics to offer CRO services
Samsung Biologics Co., the world’s largest contract drugmaker, will enter the contract research organization (CRO) market by leveraging its va...
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
Chong Kun Dang to build new plant for foray into biologics market
Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Lotte Biologics eyes first ADC CDMO order in 2025
SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US
South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...
Yuhan’s lung cancer drug gets OK in Europe
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
Celltrion BioSolutions launched to venture into CDMO
Celltrion Inc. on Tuesday launched its contract development and manufacturing organization unit Celltrion BioSolutions Co. in its foray into the CDM...
Boryung, Lotus Pharma signs CDMO deal on anticancer injection
South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...
SK Pharmteco bags obesity treatment deal worth up to $1.4 bn
SK Pharmteco Co., a contract development and manufacturing organization (CDMO), has secured an obesity treatment order worth up to 2 trillion won ($...
SK Biopharm submits NDA of epilepsy drug to China
South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...
Celltrion to break ground on CDMO plant in 2025: Chairman Seo
South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...
Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug
Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...
Hanmi Pharma to move up launch of anti-obesity drug
South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...
Samsung Biologics wins $668 million CDMO deal with European pharma
Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...
Celltrion to establish CDMO subsidiary
Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organiza...
Celltrion's anti cancer drugs hold 90% market share in C.America
South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....
Celltrion earmarks billions of dollars to build CDMO plant: chairman
Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...
Celltrion chairman announces venture into CDMO market
South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the com...
Lotte to restructure bio business to focus on CDMO
South Korea’s retail-to-chemical conglomerate Lotte Group will restructure its bio business to focus on the profit-making medicine bio develop...
Yuhan’s lung cancer drug clears FDA hurdle for global debut
A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...
IMBiologics transfers autoimmune disease drug tech to Huadong Pharma
South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...
Costco sells Celltrion's Yuflyma Low WAC in US
South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...
